Feline restrictive orbital myofibroblastic sarcoma treated with toceranib phosphate (Palladia) as adjuvant chemotherapy: A case study of one cat

Key Clinical Message This is the first case report of treatment with toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS. This reported case highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS. Feline restrictive orbital myofibroblastic sarcoma (FROMS) is a rare aggressive tumor in cats. We explored the effectiveness of using toceranib phosphate as postsurgical adjuvant chemotherapy for advanced FROMS in a 7‐year‐old cat. Despite treatment, the cat died 4 months after surgery. This report highlights the need for further studies on the efficacy of toceranib phosphate as adjuvant chemotherapy for FROMS. Clinical findings of the cat during the clinical course. (A) At initial presentation, blepharospasm in the right eye was observed. (B) On Day 19, corneal ulceration at dorsal site did not improve, and restriction of the eyelids was prominent. (C, D) On Day 75, exposure keratitis in the right eye deteriorated due to persisting eyelid restriction, and resistance to posterior ocular compression was observed.